\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.<\/p>\n
\n\u201cThe external validation of our Discovery Engine through our collaboration with AbbVie underlines the need for disruptive technologies that can shape the progress of cancer research. To that end, we are proud to further highlight the formation of Immunome\u2019s Antibody-Drug Conjugate and T Cell Redirection Advisory Board that will help us prioritize selection of novel targets for ADCs and TCRs,\u201d stated Purnanand Sarma, Ph.D., President and CEO of Immunome. \u201cThe validation we have received so far makes us truly excited about the potential of our Discovery Engine, and we continue to leverage this within our existing oncology pipeline and in existing and potential future strategic collaborations.\u201d<\/p>\n
Highlights<\/b><\/p>\n Financial Highlights<\/b><\/p>\n About Immunome<\/b><\/p>\n \nImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company\u2019s focus is on discovering and developing therapeutics in oncology internally and in collaboration with our partners. For more information, please visit www.immunome.com<\/a> or follow us on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release contains \u201cforward-looking statements\u201d intended to qualify for the \u201csafe harbor\u201d from liability established by the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, without limitation, express or implied statements that are not historical fact regarding matters such as: Immunome\u2019s and its collaborators\u2019 ability to achieve anticipated discovery, development and commercial milestones; the timing and results of preclinical studies and clinical trials; regulatory submissions and actions; translation of preclinical data into clinical safety and efficacy; and therapeutic potential and benefits of, and possible need and demand for, Immunome\u2019s programs and development candidates. Forward-looking statements may be identified by the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ccan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cseek,\u201d \u201cpotential\u201d and similar words, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on Immunome\u2019s current expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to Immunome\u2019s ability to execute on its strategy, R&D efforts and collaborations with third parties, Immunome\u2019s ability to fund operations and raise capital; Immunome\u2019s reliance on vendors; the competitive landscape and the additional risks and uncertainties set forth more fully under the caption \u201cRisk Factors\u201d in Immunome\u2019s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 16, 2023, and elsewhere in Immunome\u2019s other filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In this press release, we may discuss our current and potential future product candidates that have not yet completed clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority, including expectations about their therapeutic potential and benefits thereof. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.<\/p>\n IMMUNOME, INC. \n44,424<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n20,323<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,112<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,326<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n46,536<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n22,649<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n916<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n681<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n230<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n284<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n100<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n100<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n332<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n332<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n48,114<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24,046<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,310<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,400<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,306<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n4,931<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n18,215<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24,831<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n7,331<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n9,421<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n62<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n34,252<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n7,393<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n134,132<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n132,653<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(120,271<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(116,001<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n13,862<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n16,653<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n48,114<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n24,046<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n IMMUNOME, INC. 2023<\/b><\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n \n2,364<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u2014<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,913<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n8,078<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n2,922<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n3,576<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n6,835<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n11,654<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,471<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(11,654<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n201<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n1<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(4,270<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(11,653<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(0.35<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n(0.96<\/p>\n<\/td>\n \n)<\/p>\n<\/td>\n \n12,182,478<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n12,122,903<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230505005072\/en\/<\/a><\/span><\/p>\n Immunome Contact Investor Contact\n
\n
\n
\n \n
\n
Condensed Balance Sheets
\n
(In thousands, except share data)
\n
(unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n March 31, 2023<\/b><\/td>\n \n December 31, 2022<\/b><\/td>\n \n <\/tr>\n \n Assets<\/b><\/td>\n \n \n \n \n \n \n <\/tr>\n \n Current assets:<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n <\/tr>\n \n Prepaid expenses and other current assets<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total current assets<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Property and equipment, net<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Operating right-of-use asset, net<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Restricted cash<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Deferred offering costs<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total assets<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n <\/tr>\n \n Liabilities and stockholders\u2019 equity<\/b><\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Current liabilities:<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n <\/tr>\n \n Accrued expenses and other current liabilities<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Deferred revenue, current<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total current liabilities<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Deferred revenue, non-current<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Other long-term liabilities<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total liabilities<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Commitments and contingencies (Note 7)<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Stockholders\u2019 equity:<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2023 and December 31, 2022, respectively<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,194,184 and 12,128,843 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Additional paid-in capital<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Accumulated deficit<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total stockholders\u2019 equity<\/td>\n \n \n \n \n \n \n \n \n \n <\/tr>\n \n Total liabilities and stockholders\u2019 equity<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n \n <\/tr>\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n<\/table>\n \n
\n \n
\n
Condensed Statements of Operations
\n
(In thousands, except share and per share data)
\n
(unaudited)<\/b><\/p>\n<\/td>\n<\/tr>\n\n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n Three Months Ended March 31,<\/b><\/td>\n <\/tr>\n \n \n \n \n \n \n <\/tr>\n \n Collaboration revenue<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n <\/tr>\n \n Operating expenses:<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Research and development<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n General and administrative<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Total operating expenses<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Loss from operations<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Interest income<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n \n Net loss<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n <\/tr>\n \n Per share information:<\/td>\n \n \n \n \n \n \n <\/tr>\n \n Net loss per share of common stock, basic and diluted<\/td>\n \n $<\/td>\n \n \n \n $<\/td>\n \n \n <\/tr>\n \n Weighted-average common shares outstanding, basic and diluted<\/td>\n \n \n \n \n \n \n \n \n <\/tr>\n<\/table>\n <\/p>\n
\n<\/b>
Corleen Roche
\n
Chief Financial Officer
\n
Immunome, Inc.
\n
investors@immunome.com<\/a><\/p>\n
\n
<\/b>Laurence Watts
\n
Managing Director
\n
Gilmartin, LLC
\n
laurence@gilmartinir.com<\/a><\/p>\n